Clinical trials: completed, sponsored by Bayer
Heart Failure
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED)
Objective of the study is to find the optimal dose of the once daily oral soluble guanylate cyclase stimulator (sGC) BAY1021189 for Phase III that can be given in addition to standard therapy for heart failure with reduced…
- Trial name
- NCT01951625
- Testing
- Vericiguat (BAY1021189) (1.25 mg), Vericiguat (BAY1021189) (5 mg)
- Where
- 157 sites in United States, Australia and 22 more
- Volunteers
- 456 people
- Sponsor
- Bayer
Heart Failure
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
Objective of the study is to find the optimal dose of the once daily oral soluble guanylate cyclase stimulator (sGC) BAY1021189 for Phase III that can be given in addition to standard diuretic and comorbidity treatment for heart…
- Trial name
- NCT01951638
- Testing
- Vericiguat (BAY1021189) (1.25 mg), Vericiguat (BAY1021189) (5 mg)
- Where
- 158 sites in United States, Australia and 23 more
- Volunteers
- 477 people
- Sponsor
- Bayer
Drug Interactions
Study to Learn the Effect of Drug BAY1817080 on the Way the Body Absorbs, Distributes and Excretes Another Drug Rosuvastatin in Healthy Adult Participants
Researchers in this study want to learn how the study drug BAY1817080 interacts with another drug called rosuvastatin (brand name: Crestor) and affects the way the body absorbs, distributes and excretes rosuvastatin in healthy…
- Trial name
- NCT04252300
- Testing
- Rosuvastatin, Rosuvastatin + BAY1817080
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Bayer
Computed Tomography
Study to Test the Usability of a New Injector to Administer Contrast Media Into Humans for Diagnostic Purposes
This study investigates if a new medical device, which injects contrast media and flushing solution into humans to increase the visibility of images taken of the human body for diagnostic purposes, is easier to handle, quicker…
- Trial name
- PERCENT (NCT03875469)
- Testing
- Centargo injector (BPI 1000045), Stellant MP injector
- Where
- 2 sites in Australia, Netherlands
- Volunteers
- 425 people
- Sponsor
- Bayer
Non-Valvular Atrial Fibrillation
Study to Gather Information on the Kidney Function of Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem) Treated With Rivaroxaban or Vitamin K Antagonists
By evaluating routine clinical practice data from the UK primary care database, researchers in this study want to gather information on the kidney function of patients with non-valvular atrial fibrillation (NVAF, irregularly…
- Trial name
- ANTENNA (NCT04297072)
- Testing
- Rivaroxaban (Xarelto, BAY-597939), VKAs
- Where
- United Kingdom
- Volunteers
- 25,000 people
- Sponsor
- Bayer
Healthy Volunteers, Psoriasis
A Multiple Dose Study of BAY1834845 in Healthy Male Subjects and in Patients With Psoriasis
To assess safety and tolerability of multiple oral doses of BAY1834845 in healthy male subjects (Part 1) and in patients with psoriasis (Part 2).
- Trial name
- NCT03493269
- Testing
- BAY1834845, Midazolam
- Where
- 2 sites in Germany
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Bayer
Pulmonary Arterial Hypertension
Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy
To demonstrate the effectiveness of riociguat as replacement of phosphodiesterase-5 inhibitors (PDE-5i) therapy in pulmonary arterial hypertension (PAH) patients
- Trial name
- REPLACE (NCT02891850)
- Testing
- Riociguat (Adempas, BAY63-2521), Sildenafil, Tadalafil
- Where
- 81 sites in United States, Austria and 19 more
- Volunteers
- 225 people
- Sponsor
- Bayer
Cough
Repeat Doses of BAY1902607 in Healthy Males and Proof of Concept in Chronic Cough Patients
The primary objectives of this study: To investigate the safety and tolerability of ascending repeated oral doses of BAY1902607 in healthy subjects (Part 1).
- Trial name
- NCT03535168
- Testing
- BAY1902607, Midazolam
- Where
- 8 sites in Netherlands, United Kingdom
- Volunteers
- 59 people
- Sponsor
- Bayer
Allergic Rhinitis
A Study to Evaluate Cooling Sensation of an Allergy Product in Adults With a History of Allergies
In this study, researchers were primarily interested in evaluating the level of agreement of cooling sensation provided by this chewable, flavored, allergy medicine.
- Trial name
- NCT04162795
- Testing
- Loratadine (Claritin, BAY76-2211)
- Where
- United States
- Volunteers
- 468 people
- Sponsor
- Bayer
Colorectal Cancer, Cardiovascular Disease
Study to Develop a Prediction Model to Understand the Effect of Low-dose Aspirin on Cancer That Develops in the Colon and/or the Rectum, Diseases That Affects the Heart or Blood Vessels and Safety Outcomes in European Countries. The Study is Also Called PEACOS Model EU
In this study researchers want to learn more about the effect of low-dose Aspirin on cancer that develops in the colon (the longest part of the large intestine) and/or the rectum (the last several inches of the large intestine…
- Conditions
- Colorectal Cancer, Cardiovascular Disease, Bleeding
- Trial name
- PEACOCS (NCT03904732)
- Testing
- Acetylsalicylic Acid (Aspirin, BAYE4465)
- Where
- United Kingdom
- Volunteers
- 2,000,000 people
- Sponsor
- Bayer
Anemia, Renal Insufficiency, Chronic
Maintenance Treatment of Renal Anemia in Dialysis Subjects
The purpose of this study is to evaluate the efficacy and safety of molidustat in comparison to darbepoetin alfa in dialysis subjects with renal anemia who are treated with Erythropoiesis-Stimulating Agents (ESAs).
- Trial name
- MIYABI HD-M (NCT03543657)
- Testing
- Molidustat (BAY85-3934), Darbepoetin alfa
- Where
- 53 sites in Japan
- Volunteers
- 229 people
- Sponsor
- Bayer
Carcinoma, Renal Cell
A Phase II Uncontrolled Study of BAY73-4506 in Previously Untreated Patients With Metastatic or Unresectable RCC
This is a uncontrolled, open-label, non-randomized Phase II study of oral BAY73-4506 to evaluate the response rate of BAY73-4506 in previously untreated patients with metastatic or unresectable renal cell cancer (RCC).
- Trial name
- NCT00664326
- Testing
- Regorafenib (Stivarga, BAY73-4506)
- Where
- 18 sites in United States, Finland and 4 more
- Volunteers
- 49 people
- Sponsor
- Bayer
Anemia, Renal Insufficiency, Chronic
A Study of Molidustat for Maintenance Treatment of Renal Anemia in Non-dialysis Subjects
The purpose of this study is to evaluate the efficacy and safety of molidustat in non-dialysis subjects previously treated with Erythropoiesis-Stimulating Agents (ESAs)
- Trial name
- MIYABI ND-M (NCT03350347)
- Testing
- Molidustat (BAY85-3934), Darbepoetin alfa
- Where
- 59 sites in Japan
- Volunteers
- 164 people
- Sponsor
- Bayer
Anemia, Renal Insufficiency, Chronic
A Study of Molidustat for Correction of Renal Anemia in Non-dialysis Subjects
The purpose of this study is to evaluate the efficacy and safety of molidustat in non-dialysis subjects with renal anemia who are not treated with Erythropoiesis-Stimulating Agents (ESAs).
- Trial name
- MIYABI ND-C (NCT03350321)
- Testing
- Molidustat (BAY85-3934), Darbepoetin alfa
- Where
- 61 sites in Japan
- Volunteers
- 162 people
- Sponsor
- Bayer
Gastrointestinal Stromal Tumors
Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)
A randomized, double-blind, placebo-controlled phase III study of regorafenib plus best supportive care versus placebo plus best supportive care for subjects with metastatic and/or unresectable gastrointestinal stromal tumors…
- Trial name
- GRID (NCT01271712)
- Testing
- Regorafenib (Stivarga, BAY73-4506), Best supportive care
- Where
- 57 sites in United States, Austria and 15 more
- Volunteers
- 199 people
- Sponsor
- Bayer
Anemia, Renal Insufficiency, Chronic
A Study of Molidustat for Treatment of Renal Anemia in Peritoneal Dialysis Subjects
The purpose of this study is to evaluate the efficacy and safety of molidustat in peritoneal dialysis subjects with renal anemia
- Trial name
- MIYABI PD (NCT03418168)
- Testing
- Molidustat (BAY85-3934)
- Where
- 27 sites in Japan
- Volunteers
- 51 people
- Sponsor
- Bayer
Anemia, Renal Insufficiency, Chronic
A Study of Molidustat for Correction of Renal Anemia in Dialysis Subjects
The purpose of this study is to evaluate the efficacy and safety of Molidustat in dialysis subjects with renal anemia who are not treated with Erythropoiesis-Stimulating Agents (ESAs)
- Trial name
- MIYABI HD-C (NCT03351166)
- Testing
- Molidustat (BAY85-3934)
- Where
- 20 sites in Japan
- Volunteers
- 25 people
- Sponsor
- Bayer
Menorrhagia, Dysmenorrhea
Prospective, Non-interventional, Multi-center Safety Study of Mirena for Heavy Menstrual Bleeding and Dysmenorrhea
The primary objective in this study is collecting post-marketing information on the safety. Thus, it includes information under the routine clinical practice on adverse events (AEs) and adverse drug reactions (ADRs) including…
- Trial name
- J-MIRAI (NCT02475356)
- Testing
- Levonorgestrel IUS (Mirena, BAY86-5028)
- Where
- Japan
- Volunteers
- 601 people
- Sponsor
- Bayer
Healthy Volunteers
A Trial to Learn How Much Rivaroxaban Gets Into the Blood When Taken in Different Forms and How Safe They Are in Healthy Men
Researchers are looking for a better way to treat venous thromboembolic disease, also known as VTE. In people with VTE, blood clots form in the veins of the legs, groin, or arms.
- Trial name
- NCT04727021
- Testing
- 20 mg tablet rivaroxaban, 20 mg rivaroxaban, granules for oral suspension
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bayer
Anemia
Single Dose Group Stratified Study in Renal Impaired and Healthy Aged and Gender Matched Subjects
Safety, tolerability, pharmacokinetics and pharmacodynamics will be investigated in a single dose group stratified study in renal impaired and healthy subjects.
- Trial name
- NCT01318551
- Testing
- BAY85-3934
- Where
- Germany
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.